Metformin and Prostate Cancer: a New Role for an Old Drug

Jessica Whitburn1, Claire M Edwards2, Prasanna Sooriakumaran2,3

  • 1Nuffield Department of Surgical Sciences, University of Oxford, Botnar Research Centre Old Road, Oxford, OX3 7LD, UK. jesswhitburn@gmail.com.

Abstract

Insights

Metformin shows potential as an anti-cancer agent, particularly for prostate cancer. Ongoing trials are evaluating its effectiveness, especially as an adjuvant therapy alongside androgen deprivation therapy (ADT).

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Epidemiological studies suggest metformin may reduce cancer incidence and mortality.
  • Growing interest in understanding metformin's anti-cancer mechanisms and therapeutic potential.

Purpose of the Study:

  • To review current evidence on metformin's role in prostate cancer therapy.
  • To explore metformin's potential as an anti-cancer agent in prostate cancer treatment.

Main Methods:

  • Review of preclinical studies on metformin's antineoplastic effects.
  • Analysis of retrospective epidemiological data in prostate cancer.
  • Evaluation of ongoing clinical trials investigating metformin's efficacy.

Main Results:

  • Preclinical studies show metformin has antineoplastic effects via various molecular mechanisms.
  • Epidemiological data for prostate cancer is mixed, but clinical trials are underway.
  • Early studies indicate metformin can inhibit cancer cell proliferation and improve metabolic syndrome in patients on androgen deprivation therapy (ADT).

Conclusions:

  • Evidence for metformin in prostate cancer therapy is rapidly accumulating.
  • Randomized trial data is still pending, but metformin shows promise as an adjuvant agent, especially for patients on ADT.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
746
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
684
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
550